In two initial phase 1 studies (Single Ascending Dose Study of PCSK-9 Inhibitor [IBI306] in Healthy Subjects, NCT03366688 and Multiple Ascending Dose Study of PCSK-9 Inhibitor [IBI306] in Chinese Patients With Hypercholesterolemia, NCT03815812), fifty-eight healthy volunteers (phase 1a) received a single dose of Tafolecimab at 25, 75, 150, 300, 450, or 600 mg subcutaneously, 75 or 450 mg intravenously, or placebo. Here, PCSK9 is linked to Hypercholesterolemia.